Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFECT trial of baricitinib versus first TNF inhibitor in tight-control rheumatoid arthritis
2019-000505-72Phase 4Completed
- Sponsor
- Transparency in Healthcare
- Start
- Feb 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of baricitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Transparency in Healthcare. Primary endpoint: ACR50 response at 12 weeks. Started Feb 2019; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-000505-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000505-72.